Where Alnylam Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Benzinga · 1d ago
Alnylam stock dips as Guggenheim slashes rating over mismatched risk/reward on upcoming trial results
Alnylam Pharmaceuticals (NASDAQ:ALNY) stock dipped ~2% on June 27 after Guggenheim downgraded the RNAi therapy maker's shares to Neutral from Buy, citing unfavorable risk/reward. The SA Quant Rating on ALNY is Hold, which
Seekingalpha · 1d ago
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Benzinga · 1d ago
Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral From Buy
MT Newswires · 1d ago
A Look Into Foreign Direct Investment Trends
Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.
Investopedia · 4d ago
The Petri Dish: Amylyx, Alnylam net drug approvals
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get over...
American City Business Journals · 06/16 14:11
Alnylam under catalyst watch at Bank of America ahead of key readout
Bank of America has opened a 90-day catalyst watch for Alnylam Pharmaceuticals as the RNAi therapeutics company plans to share topline data from a late-stage trial for experimental therapy patisiran
Seekingalpha · 06/15 14:02
SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $98 From $96, Maintains Market Perform Rating
MT Newswires · 06/15 06:03
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Zacks · 06/14 15:12
Alnylam RNAi therapy for rare protein disorder gets FDA approval
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals' (NASDAQ:ALNY) RNAi therapy Amvuttra (vutrisiran) to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The approval comes almost a
Seekingalpha · 06/14 09:56
Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY)  lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Benzinga · 06/14 00:10
BRIEF-Alnylam Announces FDA Approval Of Amvuttra (Vutrisiran) · 06/13 23:24
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
CAMBRIDGE, Mass., June 13, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA™ (vutrisiran), an RNAi therapeutic administered via sub...
Business Wire · 06/13 23:22
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Zacks · 06/10 14:51
Alnylam says kidney disease therapy led to 37% drop in key indicator
Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech focused on RNA interference announced Thursday that its experimental RNAi therapy cemdisiran caused a 37% mean reduction of an important indicator of disease progression in
Seekingalpha · 06/09 11:22
BRIEF-Alnylam Reports Results From Phase 2 Study Of IgA Nephropathy Treatment · 06/09 11:07
Alnylam Reports Topline Results From Phase 2 Study Of Investigational Cemdisiran For The Treatment Of IgA Nephropathy
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced today topline results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is in
Benzinga · 06/09 11:04
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
CAMBRIDGE, Mass., June 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today topline results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is in developm...
Business Wire · 06/09 11:00
William Blair initiates Alnylam Pharmaceuticals with outperform rating
Brokerage William Blair on Tuesday initiated an outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, while estimating a fair value for the shares of $190, which represents a 44.3% upside to
Seekingalpha · 06/07 18:17
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
Benzinga · 06/07 14:14
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.